RT Journal Article
SR Electronic
T1 SARS-CoV-2 variants of concern are associated with lower RT-PCR amplification cycles between January and March 2021 in France
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.19.21253971
DO 10.1101/2021.03.19.21253971
A1 Roquebert, Benedicte
A1 Haim-Boukobza, Stéphanie
A1 Trombert-Paolantoni, Sabine
A1 Lecorche, Emmanuel
A1 Verdurme, Laura
A1 Foulongne, Vincent
A1 Burrel, Sonia
A1 Alizon, Samuel
A1 Sofonea, Mircea T.
YR 2021
UL http://medrxiv.org/content/early/2021/03/20/2021.03.19.21253971.abstract
AB SARS-CoV-2 variants raise concern regarding the mortality caused by COVID-19 epidemics. We analyse 88,375 cycle amplification (Ct) values from variant-specific RT-PCR tests performed between January 26 and March 13, 2021. We estimate that on March 12, nearly 85% of the infections were caused by the V1 variant and that its transmission advantage over wild type strains was between 38 and 44%. We also find that tests positive for V1 and V2/V3 variants exhibit significantly lower cycle threshold (Ct) values.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04738331Funding StatementWe thank the ETE modelling team for discussion, as well as the CNRS, the IRD, the ANR, and the Region Occitanie for funding (PHYEPI grant).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Internal Review Board of the CHU of Montpellier (ClinicalTrial.gov identier NCT04738331)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and scripts used for the analysis will be shared upon peer-reviewed publication.